Tauvid™: The first FDA-approved pet tracer for imaging tau pathology in Alzheimer’s disease
Open access
Datum
2021-02Typ
- Review Article
Abstract
Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic. Mehr anzeigen
Persistenter Link
https://doi.org/10.3929/ethz-b-000471292Publikationsstatus
publishedExterne Links
Zeitschrift / Serie
PharmaceuticalsBand
Seiten / Artikelnummer
Verlag
MDPIThema
tauvid™; [18F]flortaucipir; alzheimer’s disease; tau neurofibrillary tangles (NFTs); PETOrganisationseinheit
03688 - Schibli, Roger / Schibli, Roger